Artificial intelligence for drug discovery.
Numerion Labs is an AI-native company accelerating the discovery of life-saving medicines through the development and use of cutting-edge machine learning algorithms. The company unites computational chemistry, structural biology, and medicinal chemistry to pioneer the next generation of AI-driven drug discovery platforms.
Former Founders
Founder/CEO
Founder and CEO of A Company in Stealth Mode. Previously, cofounded Atomwise, the first company to deploy deep learning for structure-based drug design ($220+ million in funding; 100 hires; signed $5B in total partnership value with Sanofi, Bayer, Eli Lilly, etc; ran largest AI-driven drug discovery experiment w/ 600+ researchers in 30 countries). Even more previous: PhD @ U of Toronto; inventor on 15 patents + applications; IBM Research; AI for Cornell’s world champion robotic soccer team.
Founder and CEO of A Company in Stealth Mode. Previously, cofounded Atomwise, the first company to deploy deep learning for structure-based drug design ($220+ million in funding; 100 hires; signed $5B in total partnership value with Sanofi, Bayer, Eli Lilly, etc; ran largest AI-driven drug discovery experiment w/ 600+ researchers in 30 countries). Even more previous: PhD @ U of Toronto; inventor on 15 patents + applications; IBM Research; AI for Cornell’s world champion robotic soccer team.
Founder
Leveraging AI to revolutionize the physical sciences, Alex Levy is the CEO and co-founder of Atmo, the leading company integrating AI into global weather forecasting. Previously, he co-founded Atomwise (W15), a pioneering AI company in small molecule drug discovery, boasting over 800 active programs and $1 billion in pharmaceutical partnerships. An alumnus of the University of Toronto, he began his career by leading a computer vision research lab within the Computer Science Department.
Leveraging AI to revolutionize the physical sciences, Alex Levy is the CEO and co-founder of Atmo, the leading company integrating AI into global weather forecasting. Previously, he co-founded Atomwise (W15), a pioneering AI company in small molecule drug discovery, boasting over 800 active programs and $1 billion in pharmaceutical partnerships. An alumnus of the University of Toronto, he began his career by leading a computer vision research lab within the Computer Science Department.
